• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

    11/14/24 5:48:35 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELVN alert in real time by email
    SC 13G/A 1 tm2428137d9_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 2)*

     

    Enliven Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    29337E102

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

    x

    ¨

    Rule 13d-1(b)

    Rule 13d-1(c)

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 29337E102   Page 2 of 14

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 3 of 14

     

    1.

    Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 4 of 14

     

    1.

    Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 5 of 14

     

    1.

    Names of Reporting Persons

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 6 of 14

     

    1.

    Names of Reporting Persons

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 7 of 14

     

    1.

    Names of Reporting Persons

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 8 of 14

     

    1.

    Names of Reporting Persons

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x (1)  (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    4,026,331 (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    4,026,331 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    4,026,331 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    8.5% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

     

     

     

    CUSIP No. 29337E102   Page 9 of 14

     

    Introductory Note:  This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Common Stock of Enliven Therapeutics, Inc.

     

    Item 1.
      (a)

    Name of Issuer

    Enliven Therapeutics, Inc.

     
      (b)

    Address of Issuer’s Principal Executive Offices

    6200 Lookout Road

    Boulder, CO 80301

     
    Item 2.
      (a)

    Name of Person Filing

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence
         
        New York Office: Palo Alto Office:
           
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018  

     

      (c)

    Citizenship

    All of the Venrock Entities were organized in Delaware. The individuals are each United States citizens.

     
      (d)

    Title of Class of Securities

     

    Common Stock, par value $0.001 per share

     
      (e)

    CUSIP Number

     

    29337E102

     

     

     

     

    CUSIP No. 29337E102   Page 10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
     
    Item 4. Ownership
       
      (a) Amount beneficially owned as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   4,026,331(1)
    VHCP Co-Investment Holdings III, LLC   4,026,331(1)
    Venrock Healthcare Capital Partners EG, L.P.   4,026,331(1)
    VHCP Management III, LLC   4,026,331(1)
    VHCP Management EG, LLC   4,026,331(1)
    Nimish Shah   4,026,331(1)
    Bong Koh   4,026,331(1)

     

    (b)Percent of class as of September 30, 2024:

     

    Venrock Healthcare Capital Partners III, L.P.   8.5%(2)
    VHCP Co-Investment Holdings III, LLC   8.5%(2)
    Venrock Healthcare Capital Partners EG, L.P.   8.5%(2)
    VHCP Management III, LLC   8.5%(2)
    VHCP Management EG, LLC   8.5%(2)
    Nimish Shah   8.5%(2)
    Bong Koh   8.5%(2)

     

      (c) Number of shares as to which the person has, as of September 30, 2024:
         
        (i) Sole power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

     

     

     

    CUSIP No. 29337E102   Page 11 of 14

     

        (ii) Shared power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   4,026,331(1)
    VHCP Co-Investment Holdings III, LLC   4,026,331(1)
    Venrock Healthcare Capital Partners EG, L.P.   4,026,331(1)
    VHCP Management III, LLC   4,026,331(1)
    VHCP Management EG, LLC   4,026,331(1)
    Nimish Shah   4,026,331(1)
    Bong Koh   4,026,331(1)

     

        (iii) Sole power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

        (iv) Shared power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   4,026,331(1)
    VHCP Co-Investment Holdings III, LLC   4,026,331(1)
    Venrock Healthcare Capital Partners EG, L.P.   4,026,331(1)
    VHCP Management III, LLC   4,026,331(1)
    VHCP Management EG, LLC   4,026,331(1)
    Nimish Shah   4,026,331(1)
    Bong Koh   4,026,331(1)

     

    (1)Consists of (i) 878,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 87,930 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 3,059,419 shares held by Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.
       
    (2)This percentage is calculated based upon 47,237,207 shares of the Issuer’s Common Stock outstanding as of August 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 13, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨

     

     

     

     

    CUSIP No. 29337E102   Page 12 of 14

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP No. 29337E102   Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
         
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings III, LLC    
         
    By: VHCP Management III, LLC    
    Its: Manager    
         
    By: /s/ Sherman G. Souther    
      Name: Sherman G. Souther    
      Its: Authorized Signatory    
         
    VHCP Management III, LLC   VHCP Management EG, LLC
         
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Nimish Shah    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    
         
    Bong Koh    
         
    /s/ Sherman G. Souther    
    Sherman G. Souther, Attorney-in-fact    

     

     

     

     

    CUSIP No. 29337E102   Page 14 of 14

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on March 13, 2023)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed March 13, 2023)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on March 13, 2023)

     

     

     

    Get the next $ELVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELVN

    DatePrice TargetRatingAnalyst
    12/13/2024$42.00Buy
    BTIG Research
    9/9/2024$37.00Buy
    H.C. Wainwright
    6/11/2024$32.00Outperform
    Robert W. Baird
    4/9/2024$34.00Buy
    Mizuho
    3/29/2023$27.00Buy
    Jefferies
    3/3/2023Outperform
    TD Cowen
    More analyst ratings

    $ELVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

      BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

      4/9/24 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Enliven Therapeutics Inc.

      DEFA14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

      4/28/25 4:08:39 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Enliven Therapeutics Inc.

      DEF 14A - Enliven Therapeutics, Inc. (0001672619) (Filer)

      4/28/25 4:05:39 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Enliven Therapeutics Inc.

      S-8 - Enliven Therapeutics, Inc. (0001672619) (Filer)

      3/13/25 5:05:55 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ELVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:48:35 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 5:46:11 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

      SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

      11/14/24 4:24:01 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Enliven Therapeutics with a new price target

      BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

      12/13/24 7:38:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enliven Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

      9/9/24 7:29:47 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Enliven Therapeutics with a new price target

      Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00

      6/11/24 7:13:48 AM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

      BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details  Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:

      4/2/25 4:03:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, inclu

      3/13/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

      BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a clin

      2/25/25 4:05:00 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Lyssikatos Joseph P sold $150,391 worth of shares (7,500 units at $20.05) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/5/25 6:43:44 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Kintz Samuel sold $150,415 worth of shares (7,500 units at $20.06) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      5/5/25 6:42:17 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Hohl Benjamin exercised 3,250 shares at a strike of $2.48 and sold $60,738 worth of shares (3,250 units at $18.69) (SEC Form 4)

      4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

      4/30/25 6:59:53 PM ET
      $ELVN
      Biotechnology: Pharmaceutical Preparations
      Health Care